Biomedical Advanced Research and Development Authority (BARDA)
VC Fund
Washington, United States
Biomedical Advanced Research and Development Authority (BARDA) is a VC fund in Washington focused on Biotechnology and Health Care. The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for publichealth medical emergencies.
- Total investments:
- 75
- Last investment:
- Lead investor:
- 92%
Last updated:
For AI agents: llms.txt
Industries Biomedical Advanced Research and Development Authority (BARDA) invests in
Stages Biomedical Advanced Research and Development Authority (BARDA) invests in
Countries Biomedical Advanced Research and Development Authority (BARDA) invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Rick Bright
|
|||
Investment Focus
Industry
- Biotechnology 38 (51%)
- Health Care 35 (47%)
- Medical 20 (27%)
- Pharmaceutical 11 (15%)
- Therapeutics 9 (12%)
Stage
- Grant 48 (64%)
- Post-IPO Equity 2 (3%)
- Funding Round 1 (1%)
- Venture - Series Unknown 1 (1%)
Country
- United States 42 (56%)
- France 2 (3%)
- Italy 1 (1%)
- Israel 1 (1%)
- Sweden 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Rick Bright
Director
|
Director | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Basilea Pharmaceutica
|
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas ofbacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options. | $30M / Grant / Jul 29, 2026 | |
Sapphiros
|
Sapphiros invests in growth-stage diagnostic companies, focusing on technologies that prioritize innovation and patient-centric approaches. The company possesses a portfolio of capabilities and technologies encompassing innovative sample collection, next-generation diagnostics, computational biology, and printed electronics. These elementscontribute to the global accessibility of crucial diagnostic results for consumers. | $12.4M / Grant / Jul 14, 2026 | |
Spectral AI
|
Spectral MD, Inc. is a predictive analytics company that develops proprietary AI algorithms and optical technology for wound healing predictions. Using its DeepView® Wound Imaging Solution, an internally developed AI technology and multispectral imaging system which has received FDA Breakthrough Designation for burn indication, Spectral MD is ableto distinguish between non-healing and healing human tissue invisible to the naked eye. Spectral MD is working towards providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers (DFU) using its DeepView® Wound Imaging Solution. | $31.7M / Grant / Mar 18, 2026 | |
|
Basilea Pharmaceutica
|
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas ofbacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options. | $6M / Grant / Feb 25, 2026 | |
Cidara Therapeutics
|
Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics. The company focuses on developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Cidara Therapeutics was founded in 2012 and headquartered in San Diego, California. | $339M / Grant / Oct 03, 2025 | |
Orexo
|
Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies. | $8M / Grant / Sep 29, 2025 | |
|
Basilea Pharmaceutica
|
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas ofbacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options. | $25M / Grant / Sep 16, 2025 | |
Lumos Diagnostics
|
Lumos Diagnostics provides rapid point-of-care diagnostic solutions. It manufactures and provides commercial sales of proprietary tests. The company develops, manufactures, and commercializes proprietary in infectious and inflammatory diseases. Lumos Diagnostics was founded in 2018 and is based in Carlsbad, California. | $6.2M / Grant / Aug 31, 2025 | |
Osivax
|
Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medicalpractitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively. | $19.5M / Grant / Aug 26, 2025 | |
Rivanna Medical
|
Rivanna Medical, LLC is a Virginia-based startup company whose core mission is to commercialize innovative ultrasound technology that lowers the cost of health care, improves patient outcomes, and reduces patient risk to radiation from X-ray-based medical imaging. | $9.9M / Grant / Jul 30, 2025 | |
| See all 75 investments → | |||
Co-Investors
National Institute of Allergy and Infectious Diseases
3 deals together
Bill & Melinda Gates Foundation
1 deal together
CARB-X
1 deal together
Department of Health and Social Care (DHSC)
1 deal together
German Federal Ministry of Research, Technology and Space
1 deal together
National Institutes of Health
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Biomedical Advanced Research and Development Authority (BARDA) invest in?
Biomedical Advanced Research and Development Authority (BARDA) invests primarily in Biotechnology, Health Care and Medical startups, most often at Grant and Post-IPO Equity stage. Most of the 75 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Biomedical Advanced Research and Development Authority (BARDA)?
Public channels for Biomedical Advanced Research and Development Authority (BARDA) include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Biomedical Advanced Research and Development Authority (BARDA)?
The team at Biomedical Advanced Research and Development Authority (BARDA) includes Rick Bright (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
